The mechanisms behind the mortality associated with early antiretroviral therapy (ART) treatment in children infected perinatally with HIV are poorly understood. Researchers sought to find potential biomarkers associated with the increased mortality. They created three groups of subjects: deceased (dead HIV+, n=20), nondeceased HIV+ (HIV+, n=59) and healthy controls (n=13).
Researchers from IrsiCaixa Institute for AIDS Research presented data from a study that aimed to identify biomarkers associated with virus control during monitored antiretroviral pause (MAP) in patients with HIV.
Modex Therapeutics Inc., an Opko Health Inc. company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co. Inc., for the development of MDX-2201, Modex's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV).
Another step forward in the quest for an Epstein-Barr virus (EBV) vaccine took the form of Merck & Co. Inc.’s deal with Modex Therapeutics Inc., owned by Opko Health Inc., to advance MDX-2201 worldwide, an arrangement that brings $50 million up front for Opko plus as much as $872.5 million in milestone payments along with royalties.
The U.S. Recover program, set up in July 2022 to identify the causes of long COVID, find biomarkers of disease and discover new therapeutic targets, is now preparing to move to its next phase and begin testing potential treatments in a multi-arm, randomized, placebo-controlled trial. But with 200 different symptoms, and limited understanding of relevant system-level pathological targets, there are significant hurdles to be overcome.
A lot of focus has been put on targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT) for HIV infection treatment, but no attention has been given to targeting its ligand, CD155.
Antiretroviral (ARV) therapy suppresses HIV, but viral replication rebounds once treatment is discontinued. The redistribution of lipids in the plasma membrane to form microdomains is crucial for viral entry and biogenesis during HIV infection. Researchers at Johns Hopkins University School of Medicine found neutral sphingomyelinase 2 (nSMase2) to be a key component of the late stages of HIV viral assembly and maturation; they hypothesized that nSMase2 inhibitors could help avoid viral rebound.
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in 2019, Immorna develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA.
To date, there is a lack of consensus in anal cancer screening. DNA methylation markers zing finger protein 582 (ZNF582) and achaete-scute homolog 1 (ASCL1) have been associated with anal intraepithelial neoplasia (AIN3) and anal carcinoma risk in people with HIV infection.
RSS
